Induced pluripotent stem cells (also known as iPS cells or iPSCs) are a type of pluripotent stem cell that can be generated directly from a somatic cell. The iPSC technology was pioneered...
The iPS Cell Stock Project collects blood from donors and reprogram these blood cells into iPS cells for regenerative medicine purposes at the Facility for iPS Cell Therapy (FiT). These iPS cells undergo strict quality control and are stocked for clinical use, to be distributed upon request by academic research institutions and companies involved in the research and development of regenerative medicine using iPS cells both in Japan and overseas. Ideally, autologous iPS cells will be used for the transplantation. To do so requires the patient's ...
이번 주의 R&D News Letter 주제는 Stem cell 입니다 . 관련 그림을 클릭하시면 자세히 살펴보실 수 있습니다 !
PALO ALTO, Calif., Nov. 2, 2023 /PRNewswire/ -- Leading GMP cell CDMO I Peace, Inc. (https://www.ipeace.com), specializing in induced pluripotent stem cells (iPSCs) and iPSC-derived cell therapies...
Learn more about the iPSC media and advance your iPSC cell therapy research to clinical applications.
줄기세포(-細胞, 영어: stem cell)는 배아 또는 성체에 있는, 여러... 줄기세포(iPS cells)가 있다. 배아줄기세포 [편집] 이 부분의 본문은... 성체줄기세포 치료의 종류 [편집] 유전자 치료(gene therapy)는 특정한...
my iPS Project : Ideally, autologous iPS cells will be used for cell therapy transplantations. However, to do so necessitates the patient's own cells, such as blood cells, be reprogrammed to iPS cells and differentiated into the cell type required for transplantation. Each step involves careful cell manipulation, from reprogramming to differentiation, and requires strict quality control. To make iPS cell therapies accessible to a large population, the CiRA Foundation is developing technologies necessary to manufacture one's own iPS cells at low ...
Induced pluripotent stem cells are incredibly important in biomedicine. This blog explores iPS cells, CRISPR-Cas9 iPSCs, and challenges of iPSC gene editing.
Kallos Stem Cell Research & Therapy (2021) Animal Models and Alternatives in Vaginal Research: a Comparative Review Jennifer M. McCracken Gisele A. Calderon Julie C. E. Hakim Reproductive...
Japan-California startup Shinobi Therapeutics Inc. has emerged from stealth mode with a $51 million series A round to advance its first off-the-shelf induced pluripotent stem cell (iPS)-T cell ther...